(Q50586264)

16 March 2018

title

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon. (English)

1 reference

16 March 2018

1 reference

1 reference

Bresci G

1

1 reference

16 March 2018

Parisi G

series ordinal

2

1 reference

16 March 2018

Bertoni M

series ordinal

3

1 reference

16 March 2018

Capria A

series ordinal

4

1 reference

16 March 2018

publication date

1 November 2000

1 reference

16 March 2018

Digestive and Liver Disease

published in

1 reference

16 March 2018

volume

32

1 reference

16 March 2018

issue

8

1 reference

16 March 2018

page(s)

703-707

1 reference

16 March 2018

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Hepatitis C-associated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Treatment of chronic non-A, non-B hepatitis wih acyclovir: pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Retreatment with interferon-alpha of chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

An immunoassay for specific amplified HCV sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Interferon-ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980334-5

7 January 2021

10.1016/S1590-8658(00)80334-5

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018